Sign up
Pharma Capital

Integumen builds out Labskin AI platform with RinoCloud acquisition

Life sciences group Integumen PLC (LON:SKIN) chief executive Gerry Brandon speaks to Proactive London's Andrew Scott following the announcement they've agreed to buy scientific data management specialist, RinoCloud.

Integumen's been using RinoCloud’s technology in its development of Labskin AI – an extension of Integumen’s laboratory-grown skin product which provides real-time test results to skincare, wound care, pharma, healthcare and personal care companies.


View full SKIN profile View Profile

Integumen's digital revolution

View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.